A hybrid vesicle combining milk exosomes with functionalized liposomes achieved 2.4-fold better semaglutide loading and 8.7% oral bioavailability by adapting its surface properties to overcome sequential gut absorption barriers.
8.7% oral bioavailabilityFor semaglutide delivered via milk exosome-liposome hybrid vesicles — significantly higher than current oral peptide formulations
What the researchers found
Milk exosome-liposome hybrid vesicles (mExos@DSPE-Hyd-PMPC) achieved 2.4× semaglutide encapsulation efficiency over natural exosomes and 8.7% oral bioavailability through pH-responsive surface adaptation that overcomes sequential gut absorption barriers.
Why it matters
Oral peptide delivery is the holy grail of drug delivery — most peptide drugs require injection. Achieving 8.7% oral bioavailability for semaglutide using a milk-derived natural carrier is a major step toward needle-free peptide therapies.
The numbers in context
Hybrid vesicles significantly improved oral bioavailability compared to exosomes or liposomes alone. Published in ACS Nano.
How the study worked
Hybrid vesicles created by fusing functionalized liposomes (containing pH-sensitive hydrazone-linked zwitterionic polymer) with natural milk exosomes. Characterized for semaglutide loading, mucus penetration, epithelial barrier crossing, and oral bioavailability in animal models.
Who was studied
In vitro and animal oral drug delivery testing
What this study cannot tell us
Animal study — human gastrointestinal conditions differ from the models used. Manufacturing scalability of exosome-liposome hybrids is uncertain. Long-term stability and shelf life haven't been assessed. Regulatory pathway for milk exosome-based drug delivery is unclear.
How to read the evidence
Preliminary evidence from an animal study demonstrating proof-of-concept for the delivery platform. No human pharmacokinetic studies have been conducted.
When this study was published
Published in 2024; represents cutting-edge oral peptide drug delivery research.
The bigger picture
The oral semaglutide tablet (Rybelsus) currently achieves about 1% bioavailability and requires strict fasting. An 8.7% bioavailability platform using safe, milk-derived exosomes could dramatically improve oral peptide drug delivery across many therapeutic areas — not just GLP-1 agonists.
Questions still open
- Could this delivery platform work for other peptide drugs beyond semaglutide?
- How does the 8.7% bioavailability compare to current oral semaglutide formulations in equivalent animal models?
- Can milk exosome-liposome hybrid production be scaled for commercial pharmaceutical manufacturing?
Common questions
Why is it so hard to take peptide drugs like semaglutide by mouth?
What are milk exosomes?
Read the original research
Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.
ACS nano, 18(32), 21091-21111
Citation
Xiao, Peifu; Wang, Hanxun; Liu, Hongbing; Yuan, Haoyang; Guo, Chen; Feng, Yupeng; Qi, Pan; Yin, Tian; Zhang, Yu; He, Haibing; Tang, Xing; Gou, Jingxin. (2024). Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.. ACS nano, 18(32), 21091-21111. https://doi.org/10.1021/acsnano.4c02560